A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

NCT03976648 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped The benefit-risk profile no longer supports continuing the studies

Conditions

Systemic Sclerosis

Interventions

DRUG: GLPG1690

Sponsor

Lakefront Biotherapeutics NV